US Edition
News from urologytimes.com
We’ve assigned a media bias rating of unknown to urologytimes.com. You can read more about our methodology here.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top urologytimes.com News
DNAPatients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ctDNA-negative patients may potentially be spared unnecessary treatment. The finding is based on results from the global, randomized, phase 3 IMvigor011 trial co-led by investigators from Dana-Farber Cancer Institute, the Technical University of Mu…See the Story
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
100% Center coverage: 1 sources
